Compare Quest Diagnostics Inc (DGX) vs Sprott Uranium Miners ETF (URNM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Sprott Uranium Miners ETF — how do they compare? Quest Diagnostics Inc trades at $230.97 (market cap $25.48B), while Sprott Uranium Miners ETF trades at $46.5 (market cap $1.87B). The key difference: Quest Diagnostics Inc is far larger — about 13.6× Sprott Uranium Miners ETF's market cap, and Quest Diagnostics Inc pays a 1.49% dividend while Sprott Uranium Miners ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Sprott Uranium Miners ETF for 61 Days on average.
| DGX | URNM | |
|---|---|---|
Market Cap | $25.48B | $1.87B |
Volume | 941,866 | 1,586,926 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $247.45 | $83.99 |
52-Week Low | $173.49 | $46.09 |
Typical Hold Time | 56 Days | 61 Days |
Enterprise Value | $31.23B | — |
Dividend Yield | 1.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.81, up 1.68% today, with a bullish earnings trend after beating EPS estimates for three consecutive quarters. The stock shows a mixed technical picture with a bearish overall signal but trades near key support at $228. Revenue growth accelerated to $11.04B in 2025, and the company maintains solid profitability with a 9.19% net income margin. Recent news highlights growth in consumer testing and a partnership with Apple Health, though Medicare reimbursement cuts pose a headwind.
The outlook is cautiously optimistic, supported by strong fundamentals and a consensus price target of $250 offering 8% upside. Key opportunities include demand for advanced diagnostics and AI adoption, while risks center on regulatory pressure and rising debt levels. Analyst sentiment is mixed with a slight hold bias, reflecting balanced growth prospects against near-term challenges.
URNM (Sprott Uranium Miners ETF) trades at $46.09, down 3.72% today amid bearish technical signals. The ETF shows strong fundamental support from uranium's supply-demand imbalance and growing AI energy demand. Recent news highlights nuclear energy's resurgence, with uranium prices rising 21.25% over the past year according to Sprott Asset Management data from August 2026.
Long-term outlook remains positive due to structural uranium deficits and government nuclear investments, but short-term technical weakness and ETF volatility present near-term risks. The convergence of AI power demand and nuclear expansion creates substantial growth potential for uranium miners over the next decade.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Sprott Uranium Miners ETF
URNM is a pure-play ETF that invests in the global uranium industry. It provides exposure to companies involved in the mining, exploration, and production of uranium, as well as physical uranium holdings, with top assets like Cameco, Uranium Energy Corp, and the Sprott Physical Uranium Trust.
Read more on URNM →
